Jessica Thompson (@jlthompsonmd) 's Twitter Profile
Jessica Thompson

@jlthompsonmd

Breast Surgical Oncology @CorewellHealth ~ Training @SpectrumHealth @UMichSurgery ~ Wife and Mom ~ Tweets are my own

ID: 1464415288640913420

calendar_today27-11-2021 02:07:38

56 Tweet

120 Followers

226 Following

Laila Agrawal, MD (@lailaagrawalmd) 's Twitter Profile Photo

As a community medical oncologist, here are my top 5⃣ to bring back to my patients Monday morning after #SABCS22 SABCS OncoAlert 1. POSITIVE 🤰 2. BabyTam 👶 3. Contralateral #bcsm in gene mutation carriers 4. RIGHT - ribo in aggressive MBC 5. TMC - neo platinum 🧵

Philippe Aftimos, MD  (@aftimosp) 's Twitter Profile Photo

Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial ascopubs.org/doi/10.1200/JC… #bcsm

Dana-Farber’s Breast Oncology Center (@dfci_breastonc) 's Twitter Profile Photo

New editorial from Anna Weiss and Tari King MD in Annals of Surgical Oncology. ➡️➡️ Local Regional Recurrence Rates Are Low Following Neoadjuvant Endocrine Therapy: What Are the Remaining Barriers to its Widespread Adoption? ⬇️⬇️Read fulltext here: rdcu.be/c2UAz

New editorial from <a href="/DrAnnaWeiss/">Anna Weiss</a> and <a href="/TariKingMD/">Tari King MD</a> in Annals of Surgical Oncology. 
➡️➡️ Local Regional Recurrence Rates Are Low Following Neoadjuvant Endocrine Therapy: What Are the Remaining Barriers to its Widespread Adoption?
⬇️⬇️Read fulltext here:
rdcu.be/c2UAz
National Cancer Institute (@thenci) 's Twitter Profile Photo

February 3 is National Women Physicians Day – an event that celebrates Elizabeth Blackwell’s birthday, who was the first female medical doctor in the United States. On this day, we say thank you to all of the women in medicine who are making a difference around the world. #NWPD

February 3 is National Women Physicians Day – an event that celebrates Elizabeth Blackwell’s birthday, who was the first female medical doctor in the United States.

On this day, we say thank you to all of the women in medicine who are making a difference around the world. #NWPD
Kristin E. Rojas MD, FACS, FACOG (@kristinrojasmd) 's Twitter Profile Photo

I’m starting a national campaign to stop calling tam/AIs “chemoprevention”. I’m 100% sure leads to pts declining therapy. “Hormone therapy” is also a misnomer. Let’s call it “estrogen blockers” bc patient understand this, are more likely to anticipate side effects. Who’s with me?

Sergio Israel Aguilar (@drsergioaguilar) 's Twitter Profile Photo

🔊⚠️🔊⚠️ In the latest poll, 70% considered the use of primary sustained endocrine therapy (ET) in HR+ HER2- in #breastcancer patients older than 70yrs. Let’s check recent evidence on that published at Annals of Surgical Oncology! 🧵🧵🧵

Olga Kantor MD, MS, FACS (@okantormd) 's Twitter Profile Photo

Excellent new podcast from the Society of Surgical Oncology Fellows & Young Attendings Subcommittee — tips on preparing for the transition from trainee to faculty practice! Kimberly Washington, MD @bsparkmanMD Jennifer Tseng #SSO_FYAS surgonctoday.libsyn.com/mastering-the-…

Olga Kantor MD, MS, FACS (@okantormd) 's Twitter Profile Photo

Calling all TRAINEES attending Society of Surgical Oncology #SSO2023 - check out the Trainees Lounge, Rm 210. New this year we will have representatives from many CGSO and Breast Fellowship Programs to learn about the programs and #network! See thread below for the programs participating:

Puneet Singh, MD FACS (@puneetsinghmd) 's Twitter Profile Photo

Dr. Anita Mamtani Memorial Sloan Kettering Cancer Center presents on axillary management in cT1N0 TNBC & Her2+ breast ca. These patients may be safely selected to undergo upfront surgery w/o concern that many will be node positive & would have benefited from de-escalation of axilla w/ NACT. #SSO2023

Dr. Anita Mamtani <a href="/MSKCancerCenter/">Memorial Sloan Kettering Cancer Center</a> presents on axillary management in cT1N0 TNBC &amp; Her2+ breast ca. These patients may be safely selected to undergo upfront surgery w/o concern that many will be node positive &amp; would have benefited from de-escalation of axilla w/ NACT. #SSO2023
Puneet Singh, MD FACS (@puneetsinghmd) 's Twitter Profile Photo

.Clara R. Farley beautifully presents MD Anderson Cancer Center study on factors predicting 4 or more positive nodes in cN0 HR+/Her2- breast cancer. Important data as we try to better predict nodal burden which can impact systemic therapy decisions #ASBrS23 ASBrS

.<a href="/ClaraRFarley1/">Clara R. Farley</a> beautifully presents <a href="/MDAndersonNews/">MD Anderson Cancer Center</a> study on factors predicting 4 or more positive nodes in cN0 HR+/Her2- breast cancer.  Important data as we try to better predict nodal burden which can impact systemic therapy decisions #ASBrS23 <a href="/ASBrS/">ASBrS</a>
Dr Liz O'Riordan (@liz_oriordan) 's Twitter Profile Photo

Did you know there are 13 types of #breastcancer? In this video I go through them all, and as a bonus, I talk about the 5 ways it can be described - stage, grade etc What is Breast Cancer? youtu.be/2sK4myDbI30 via YouTube

Paolo Tarantino (@ptarantinomd) 's Twitter Profile Photo

Which should be the duration of adjuvant endocrine treatment for early-stage HR+ breast cancer? Dr. Michael Gnant nicely recapitulates the evidence & highlights the recent votes by the St. Gallen panel, with fairly clear answers. #ASCO23

Which should be the duration of adjuvant endocrine treatment for early-stage HR+ breast cancer? <a href="/MichaelGnant/">Dr. Michael Gnant</a> nicely recapitulates the evidence &amp; highlights the recent votes by the St. Gallen panel, with fairly clear answers. #ASCO23
Dana-Farber’s Breast Oncology Center (@dfci_breastonc) 's Twitter Profile Photo

#ASCO23 #BreastCancer Poster Session: ASCENT-05/OptimICE-RD: Phase 3 study of adjuvant sacituzumab govitecan + pembro vs pembro ± capecitabine in patients with #TNBC and residual disease after neoadjuvant therapy and surgery. Sara Tolaney Lisa Carey, MD, ScM, FASCO meetings.asco.org/2023-asco-annu…

#ASCO23 #BreastCancer Poster Session:
ASCENT-05/OptimICE-RD: Phase 3 study of adjuvant sacituzumab govitecan + pembro vs pembro ± capecitabine in patients with #TNBC and residual disease after neoadjuvant therapy and surgery. <a href="/stolaney1/">Sara Tolaney</a> <a href="/DrLisaCarey/">Lisa Carey, MD, ScM, FASCO</a>
meetings.asco.org/2023-asco-annu…
Society of Surgical Oncology (@socsurgonc) 's Twitter Profile Photo

Less than a week away until you can learn practical tips and tricks to help you get the most out of your fellowship! Don't miss this opportunity to maximize your potential 📈 ow.ly/rpcP50PC8rk

Less than a week away until you can learn practical tips and tricks to help you get the most out of your fellowship! Don't miss this opportunity to maximize your potential 📈 ow.ly/rpcP50PC8rk
Ilana Schlam (@ilanaschlam) 's Twitter Profile Photo

2023 was an outstanding year for breast cancer research As we start wrapping up #SABCS23, we need to think about how to incorporate what we learned in the clinic and future research. Looking forward to what is yet to come to improve outcomes for our patients! OncoAlert #BCSM

2023 was an outstanding year for breast cancer research 
As we start wrapping up #SABCS23, we need to think about how to incorporate what we learned in the clinic and future research.
Looking forward to what is yet to come to improve outcomes for our patients! 
<a href="/OncoAlert/">OncoAlert</a>  #BCSM
ASBrS (@asbrs) 's Twitter Profile Photo

It’s time to update our counseling! BCT may have a better survival and has equivalent recurrence to mastectomy. #ASBRS24

It’s time to update our counseling! BCT may have a better survival and has equivalent recurrence to mastectomy. #ASBRS24
Jessica Thompson (@jlthompsonmd) 's Twitter Profile Photo

So many informative & engaging sessions at this year's #ASBrS24! Also excited to officially ✔️off first project as PI - hopefully the geographic reach of breast specialty services can be further expanded to high risk individuals by means of telemedicine offerings in the future!

So many informative &amp; engaging sessions at this year's #ASBrS24! 

Also excited to officially ✔️off first project as PI - hopefully the geographic reach of breast specialty services can be further expanded to high risk individuals by means of telemedicine offerings in the future!
Stephanie Graff, MD, FACP, FASCO (@drsgraff) 's Twitter Profile Photo

Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial | Breast Cancer | JAMA | JAMA Network #SABCS24 ⁦OncoAlertAlliance for Clinical Trials in Oncology⁩ jamanetwork.com/journals/jama/…